Optimal prandial timing of bolus insulin in diabetes management:A review by Slattery, D. et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1111/dme.13525
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Slattery, D., Amiel, S. A., & Choudhary, P. (2017). Optimal prandial timing of bolus insulin in diabetes
management: A review. Diabetic Medicine. DOI: 10.1111/dme.13525
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 15. Dec. 2017
Review Article
Optimal prandial timing of bolus insulin in diabetes
management: a review
D. Slattery, S. A. Amiel and P. Choudhary
Kings College London, Weston Education Centre, London, UK
Accepted 12 October 2017
Abstract
The inability to achieve optimal diabetes glucose control in people with diabetes is multifactorial, but one contributor
may be inadequate control of postprandial glucose. In patients treated with multiple daily injections of insulin, both the
dose and timing of meal-related rapid-acting insulin are key factors in this. There are conflicting opinions and evidence
on the optimal time to administer mealtime insulin. We performed a comprehensive literature search to review the
published data, focusing on the use of rapid-acting insulin analogues in patients with Type 1 diabetes. Pharmacokinetic
and pharmacodynamic studies of rapid-acting insulin analogues, together with postprandial glucose excursion data,
suggest that administering these 15–20 min before food would provide optimal postprandial glucose control. Data from
clinical studies involving people with Type 1 diabetes receiving structured meals and rapid-acting insulin analogues
support this, showing a reduction in post-meal glucose levels of ~30% and less hypoglycaemia when meal insulin was
taken 15–20 min before a meal compared with immediately before the meal. Importantly, there was also a greater risk of
postprandial hypoglycaemia when patients took rapid-acting analogues after eating compared with before eating.
Diabet. Med. 00, 00–00 (2017)
Introduction
The importance of optimal glycaemic control in preventing
the micro- and macrovascular complications associated with
diabetes has been well documented [1,2]. Despite this, a
significant percentage of people with diabetes do not achieve
target glycaemic control. The UK National Diabetes Audit
2015–2016 found that HbA1c levels were >58 mmol/mol
(7.5%) in 70.8% of people with Type 1 diabetes and 34.3%
in those with Type 2 diabetes [3]. Data published in the USA
in 2013 estimated that 47.8% of people with diabetes had
HbA1c levels of >53 mmol/mol (7%) [4]. The inability to
achieve optimal glycaemic control in diabetes is multifaceted,
as highlighted by Khunti et al. [5]; however, postprandial
hyperglycaemia is one likely key contributing factor [6].
High postprandial blood glucose (BG) levels also contribute
to greater glycaemic variability, another marker of poor
glycaemic control [7]. Epidemiological studies show an
association between impaired glucose tolerance and cardio-
vascular risk and outcome [8].
Prandial insulin replacement is important. In individuals
without diabetes, prandial insulin makes up ~50% of the
total daily pancreatic output. Most of the prandial insulin is
secreted within the first hour after the meal [9]. The
International Diabetes Federation consensus statement rec-
ommends that 2-h post-meal glucose levels should not
exceed 7.8 mmol/l, as this level is seldom seen in those
without diabetes [10]. The American Diabetes Association
specifies a postprandial glucose target of 10 mmol/l at 2 h
[11]. There is evidence that postprandial glucose excursions
beyond these levels increase the risk of retinopathy [12] and
greater carotid intima-media thickness, and lead to oxidative
stress, inflammation and endothelial dysfunction [13–15].
Furthermore, there is evidence to suggest that post-meal
hyperglycaemia is also associated with decreased myocardial
blood flow and an increased risk of cancer [16,17]. Mean-
while, the pre-meal target in the intensive arm of the
Diabetes Control and Complications Trial was 3.9–
6.7 mmol/l and resulted in a significant reduction in vascular
complications [18].
In people with either Type 1 or insulin-requiring Type 2
diabetes treated with multiple daily injections (MDI),
short- or rapid-acting insulin is given with meals to cover
mealtime glucose excursions. The pharmacology of the
insulin compared with the glucose profile from the food
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ingested govern the extent of post-meal glucose excursions.
In the pre-rapid-acting insulin analogue era, regular human
insulin (RHI) was the mainstay of bolus insulin therapy;
however, recognition of its slow onset of action and
delayed peak led to the recommendation to take it
≥30 min pre-meal. In practice, many people did not do
this. To address this, rapid-acting insulin analogues were
introduced in the 1990s.
There are currently three rapid-acting analogues marketed
in the USA and Europe: insulin lispro (Humalog; Eli Lilly,
Indianapolis, IN, USA), insulin aspart (Novolog/NovoRapid;
Novo Nordisk, Bagsvaerd, Denmark) and insulin glulisine
(Apidra; Sanofi, Paris, France). Additionally, a fourth rapid-
acting analogue, fast-acting insulin aspart (faster aspart;
Fiasp; Novo Nordisk, Bagsvaerd, Denmark), has recently
been approved for marketing in Europe and other parts of
the world. For insulin lispro, proline and lysine at positions
28 and 29 on the B-chain of human insulin are reversed.
With insulin aspart, proline at position 28 on the B-chain of
human insulin is replaced with aspartic acid and for insulin
glulisine, arginine at position 3 on the B-chain is replaced
with lysine, and lysine at position 29 on the B-chain is
replaced with glutamic acid. These changes reduce the ability
of the insulin molecules to aggregate, and the dimers and
monomers are more rapidly absorbed after subcutaneous
(s.c.) injection. Next-generation and faster rapid-acting
insulin analogues have also been developed that boast
superior insulin absorption rates and early glucose-lowering
effects when compared with rapid-acting analogues. Faster
aspart is insulin aspart set in a new formulation with vitamin
B3 (also known as nicotinamide) and arginine.
Manufacturers of rapid-acting insulin analogues recom-
mend injecting immediately before food or soon thereafter,
and this is common practice for many people who feel more
confident of the amount of carbohydrate eaten after they
have eaten it [19–21]. Most structured education pro-
grammes recommend injections pre-meal, but often the
precise timing is not specified and, in clinical practice, we
observe many patients injecting their mealtime insulin post-
meal. For this reason, we conducted a systematic literature
review of studies evaluating the timing of rapid-acting insulin
in an attempt to obtain some clarity on this important topic.
Methods
Data for the present review were collected through searches
of PubMed: a specific search over the past 30 years and a
more general search over the past 10 years. A search of
ProQuest was also conducted which captured the Embase
and Biosis databases. Search terms included: ‘diabetes’,
‘diabetes mellitus’, ‘Type 2 diabetes’, ‘Type 1 diabetes’,
‘T1D’, ‘T2D’, ‘bolus insulin’, ‘prandial insulin’, ‘insulin
analogue’, ‘insulin aspart’, ‘insulin lispro’, ‘insulin glulisine’,
‘postprandial excursions’, ‘postprandial hyperglycaemia’,
‘postprandial administration’, ‘preprandial administration’,
‘post-meal administration’, ‘pre-meal administration’, ‘insulin
timing’, ‘time of dose’, ‘timing of bolus’, ‘timing of prandial’,
‘dosing’, ‘flexibility’, ‘pharmacokinetics’ and ‘pharmacody-
namics’. Studies on faster aspart were identified by the original
search. A study on BC lispro was reviewed and included after
the published search. The specific search of PubMed over the
past 30 years yielded 1432 results, and the more general
10-year search yielded 1990 results. The ProQuest search
yielded 770 results. The authors reviewed the abstracts of all
papers produced by the search and evaluated for relevance
papers that specifically looked at the glycaemic effect of timing
of rapid-acting insulin in Type 1 or Type 2 diabetes. We
identified 19 studies that could potentially be relevant to
our review, with 11 being included (Fig. 1). Additional
studies included in the review were obtained from references
of studies identified by the search.
Evidence from pharmacokinetic and
pharmacodynamic studies
Pharmacokinetic (PK) studies carried out in people with
Type 1 diabetes show that all three rapid-acting insulin
FIGURE 1 Review flow diagram.
What’s new?
• Taking rapid-acting insulin 15–20 min before a meal
provides significant improvements in post-meal control;
we recommend this whenever safely possible.
• People with diabetes who routinely bolus pre-meal have
better HbA1c values, according to large registry data.
• Post-meal bolusing may increase the risk of hypogly-
caemia.
• Advice about timing of bolus needs to be tailored in
some special circumstances (e.g. pregnancy, emergency
work, gastroparesis).
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analogues have similar PK and pharmacodynamic (PD)
profiles (Table 1) [22,23]. They demonstrate peak plasma
insulin concentrations approximately double those of RHI,
and a time to maximum concentration less than half that of
RHI, with concentrations of the analogues falling more
rapidly, returning to levels <20% of peak concentrations at
about 4 h (Fig. 2) [19–21].
One study showed little difference between the analogues:
insulin aspart reached t50% of peak(ins) at 19.6  1.7 min and
insulin lispro at 16.7  1.8 min (P = 0.29), and each ana-
logue reached tpeak(ins) at 43.8  3.9 min and
46.7  4.7 min, respectively (P = 0.66) [22]. When com-
pared with insulin aspart and insulin lispro, the PK properties
of insulin glulisine differ slightly in the majority of published
studies, with a faster onset of action observed for glulisine.
Heise et al. [23] showed that the time to 10% of total insulin
area under the curve (INS-AUC) was faster with insulin
glulisine compared with insulin lispro at either dose (0.2 U/
kg: 0.7  0.2 vs 0.8  0.2 h; 0.4 U/kg: 0.8  0.2 vs
0.9  0.2 h; P < 0.001) [23]. When compared with insulin
aspart, faster absorption rates were noted with insulin
glulisine (shorter times to 10% and 20% of INS (max);
P = 0.0005 each) [24].
Heise et al. [25] also investigated the PK properties of
faster aspart, comparing it with insulin aspart. A faster initial
onset of absorption of faster aspart vs insulin aspart was
supported by a significantly earlier onset of appearance (4.9
vs 11.2 min) and time to reach half the maximum concen-
tration (t50%Cmax(ins) 20.7 vs 31.6 min). With faster aspart,
the time to onset of appearance and t50%Cmax(ins) were
reduced by 57% and 35%, respectively, compared with
insulin aspart. The tmax(ins) for faster aspart was 62.9 min
and, for insulin aspart, it was 69.7 min (Fig. 2) [25].
Andersen et al. [26] looked at the PK properties of ultra-
rapid BC lispro vs insulin lispro (0.4 U/kg vs 0.2 U/kg).
Onset of action was significantly earlier with BC lispro when
compared with insulin lispro, with a median (min;max) t50%
Cmax(ins) of 15 (6;32) vs 27 (12;43) min, respectively. The
median (min;max) tmax(ins) for BC lispro was 45 (25;120) min
and for insulin lispro it was 60 (25;105) min (Fig. 2) [26].
In clinical practice, PD assessment holds more relevance
than PK assessment. The glucose-clamp technique is the ‘gold
standard’ for assessing insulin PD characteristics, providing
data on onset, peak and duration of action, which are key in
determining optimal bolus timing [27]. Euglycaemia is
maintained after insulin administration via a concomitant
intravenous glucose infusion at a variable rate. This variable
glucose infusion rate (GIR) is indicative of whole-body insulin
action. Clamp studies have demonstrated discordance
between rapid-acting insulin analogue PK properties (absorp-
tion time) and PD properties (action time), which creates an
obstacle in successfully replicating prandial, physiological
insulin action (we have not found any clinical data that
explain the differences seen between the PK and PD charac-
teristics of these insulin analogues). For example, a study
comparing PD profiles of insulin lispro 100 U/ml and insulin
lispro 200 U/ml found that, although the times to maximum
insulin concentration were 45 and 60 min, respectively, the
times to maximum GIR were similar (120 vs 126.6 min for
insulin lispro 100 vs 200 U/ml) [28]. Another study highlights
the potential difference in timing of important outcomes.
Directly comparing insulin aspart with insulin lispro, this
study demonstrated a maximum insulin concentration of
30 min for both (P = 0.24), but a maximum GIR at 120 min,
also for both (P = 0.61; Fig. 3) [29]. Swan et al. [30]
investigated the effect of puberty on the PD and PK properties
Table 1 Pharmacokinetic and pharmacodynamic studies
Study
Rapid-acting
insulin analogues
PK characteristics
INS-Tmax, min
PD characteristics
GIR-Tmax, min
Plank et al. [22] Insulin aspart
Insulin lispro
43.8  3.9
46.7  4.7
n/a
Heise et al. [23] Insulin glulisine
Insulin lispro
100  40
92  38
196  73
198  65
Arnolds et al. [24] * Insulin glulisine
Insulin aspart
90 (40–120)
90 (50–150)
186 (155–263)
156 (83–245)
Heise et al. [25] † Faster aspart
Insulin aspart
62.9 (3.73)
69.7 (3.73)
124.3 (5.87)
135.2 (5.87)
De la Pena et al. [28] ‡ Lispro 100
Lispro 200
45 (30–180)
60 (30–180)
120 (56)
126.6 (49)
Homko et al. [29] Aspart
Insulin lispro
30
30
120
120
Swan et al. [30] Insulin aspart 60 100
Andersen et al. [26]* BC lispro
Insulin lispro
45 (25–120)
60 (25–105)
109 (65–221)
117 (71–225)
Values are means (SD) unless stated otherwise. *Values are medians (range). †Values are means (SEM). ‡Values are means (CV[%]).
BC lispro, BioChaparone insulin lispro; CV[%], coefficient of variance; GIR-Tmax, time to maximum glucose infusion rate; INS-Tmax, time to
maximum serum insulin concentration; n/a, not available; PD, pharmacodynamic; PK, pharmacokinetic.
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of insulin pump therapy in adolescents, and found that the
peak action of insulin aspart was not observed until 90 min,
40 min after peak insulin concentration was reached.
The PD characteristics of faster aspart and BC lispro may
be superior when compared with their respective rapid-acting
analogue counterparts. When comparing faster aspart with
FIGURE 2 Pharmacokinetics of bolus insulins. Panels (a), (b) and (c) are reproduced from Home et al. Diabetes Obes Metab 2012; 14: 780–788.
Panel (d) is reproduced with permission from Andersen et al. EASD 2016; ePoster #931. Panels (e) and (f) are reproduced from Heise et al. Diabetes
Obes Metab 2015; 17: 682–688 [25], under a Creative Commons licence. s.c., subcutaneous.
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insulin aspart, the onset of glucose-lowering effect was
earlier with faster aspart, with a significantly earlier t50%
GIRmax (38.3 vs 46.1 min). The time to reach the peak effect,
tGIRmax, was also shorter (124.3 vs 135.2 min, ratio 0.83,
95% CI 0.73; 0.94) [25]. BC lispro displayed similar
differences compared with insulin lispro with a significantly
earlier t50%GIRmax (31 vs 42 min, respectively; P < 0.001)
and significantly earlier tGIRmax (109 vs 117 min, respec-
tively; P = 0.0005) [26].
Continuous glucose monitoring (CGM) studies have
shown that postprandial glucose levels peak at a mean of
70–80 min after eating in people with diabetes [31]. CGM
measures interstitial glucose, with a lag of 4–10 min in
relation to BG levels [32]. Although peak insulin levels are
seen 40–60 min post-injection, peak insulin action occurs
around 100–120 min after injection. Given this, it is
reasonable to expect that the optimal time to administer
rapid-acting insulin analogues is 15–20 min prior to eating,
to synchronize insulin action peaks with postprandial glucose
excursions, thus minimizing postprandial hyperglycaemia.
Evidence from clinical studies
Conflicting literature exists on optimal prandial bolus timing
in clinical practice. Two studies in particular favour injection
of prandial insulin 15–20 min before eating. Cobry et al.
[33] carried out a crossover study in 23 young people with
Type 1 diabetes (mean age 18.3  4.4 years) on insulin
pump therapy. The trial had three treatment arms: delivering
an insulin glulisine bolus by insulin pump 20 min prior to a
meal (20 min), immediately before the meal (0 min) or
20 min after meal initiation (+20 min). At 60 min, the
20 min arm showed significantly lower glycaemic excur-
sions than both the 0 min arm and the +20 min arm
(20 min = 10.0  3.70 mmol/l vs 12.33  3.27 mmol/l
and 13.1  2.59 mmol/l, respectively). At 120 min after
meal initiation, the 20 min arm likewise showed signifi-
cantly lower BG values than both the 0 min and +20 min
arms (20 min = 9.79  3.9 mmol/l vs 11.5  2.7 mmol/l
and 11.4  2.8 mmol/l, respectively; Table 2). Peak BG
levels were also significantly lower in the 20 min arm
compared with the 0 min arm and in the +20 min arm
(11.2  0.44 mmol/l) compared with the 0 min arm
(13.55  0.40 mmol/l; P = 0.0001) and the +20 min arm
(13.7  0.47 mmol/l; P < 0.0001; Fig. 4). No difference in
BG readings was observed when insulin was administered
immediately prior to the meal compared with 20 min post-
meal. Hypoglycaemic episodes recorded were highest in the
+20 min arm compared with the 0 min and 20 min arms
(five vs one vs four), respectively [33].
Luijf et al. [34] studied 10 people with Type 1 diabetes on
insulin pump therapy with a mean age of 45.5  12.1 years,
in a three-way, randomized, crossover trial. Insulin aspart was
administered at 30, 15 or 0 min before mealtime. Each
participant was provided with a breakfast similar to their
usual breakfast. Area under the glucose curve was lower in the
15 min arm (0.41  0.51 mmol/l/min) than in the30 min
arm (1.89  0.72 mmol/l/min; P = 0.029) and 0 min arm
(2.11  0.66 mmol/l/min; P = 0.030). Maximum glucose
excursion was almost 30% lower in the 15 min arm
FIGURE 3 (a): Serum insulin levels before and after subcutaneous (s.c.)
injection (at 0 min) of insulin aspart or insulin lispro in seven patients
with Type 1 diabetes. (b) Glucose infusion rate (GIR) needed to
prevent hypoglycaemia in the same seven patients. (c) Plasma glucose
concentrations before and after s.c. injection of insulin aspart or insulin
lispro in the same seven patients. Figure reproduced from Homko et al.
Diabetes Care 2003; 26: 2027–2031 [33].
ª 2017 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK. 5
Research article DIABETICMedicine
(4.77  0.52 mmol/l) than in the 30 min arm
(6.48  0.76 mmol/l; P = 0.025) and 0 min arm
(6.93  0.76 mmol/l; P = 0.022). Time spent in the +3.5 to
+10 mmol/l range was higher in the 15 min arm
(224.5  25.0 min) than in the 0 min arm (90.5  23.2 min;
P = 0.001). There was no significant difference in occurrence
of hypoglycaemia between arms (P = 0.901) [34].
While both these studies were performed exclusively in
people using insulin pumps, the results should be applicable
to people using MDI regimens, as the bolus aspect of these
therapies is very similar. Importantly, participants in both of
these studies had quite tight glucose control immediately
prior to commencement of the study: 5.5–10 mmol/l in the
Cobry et al. [33] study and 3.5–7.8 mmol/l in the Luijf et al.
study [34]. In the former, test meals consisted of a known,
fixed amount of carbohydrate that was not specified and
<20 g of fat. The protein content was not revealed. In the
latter study, the nutritional content of the meal was not
mentioned, which is an important missing variable. The
infusion sites of the pumps were also not mentioned.
Several studies have compared preprandial (immediately
before eating) and postprandial administration of rapid-
acting insulin analogues (Table 2). Brunner et al. [35]
compared insulin aspart administered immediately before
(0 min) and 15 min after the start of the meal, along with
RHI 15 min before and immediately before the meal [35].
This was a well-designed study in which participants’ glucose
levels were kept within a range of 100.8–140.4 mg/dl (5.6–
7.8 mmol/l) prior to commencement, with a variable insulin
infusion. A standardized breakfast was used (543 kcal, 55%
carbohydrate, 17% protein and 28% fat). That study
showed that insulin aspart at 0 min was superior to insulin
aspart at +15 min and was similar to RHI at 15 min. The
lowest postprandial glucose level achieved was in insulin
aspart at 0 min but was higher than most target values at
11.2 mmol/l, compared with 13.2 mmol/l with insulin aspart
at +15 min. Insulin aspart injected 15 min before mealtime
was not investigated in that study. Importantly, late hypo-
glycaemia occurred in 21% of the experiments (0 min,
n = 6; +15 min, n = 6) [35].
One of the most comprehensive studies was performed by
Schernthaner et al. [36] comparing RHI at 40, 20 and
0 min and insulin lispro at 20, 0 and +15 min on
postprandial glucose levels. Participants in that study had a
standardized meal consisting of 584.5 kcal, 45.5 g of
carbohydrate, 35 g of protein and 28 g of fat. BG excursions
at 60 min after injection were significantly lower with insulin
lispro at 20 min when compared with all other treatments,
particularly insulin lispro 0 min and +15 min (1.12  2.13
vs 0.19  1.72 vs 2.20  1.49 mmol/l, respectively). At 90
and 120 min, insulin lispro 20 min and 0 min were
superior to all other treatments, with insulin lispro 0 min
performing much better at 90 and 120 min than at 60 min
when compared with insulin lispro 20 min (1.44  1.60
Table 2 Clinical studies
Study
Rapid-acting
insulin
analogue
CSII or
MDI
Time of insulin
administration
in relation
to mealtime, min
Most effective
time at lowering
postprandial
hyperglycaemia,
min
Postprandial glucose levels,
mmol/l
Cobry et al. [33] Insulin glulisine CSII 20, 0, +20* 20 11.0  3.8 vs 13.7  3.0 vs 13.8  2.3 (max)
Luijf et al. [34] Insulin aspart CSII 30, 15, 0 15 11.74  0.8 vs 9.26  0.72 vs 12.29  0.93
(max)
Brunner et al. [35] Insulin aspart MDI 0, +15 0 11.2 (10.4–12.0) vs 13.2 (12.3–14.2) (max)
Schernthaner et al. [36] Insulin lispro MDI 20, 0, +15* 20 n/a
Jovanovic et al. [38] Insulin aspart MDI 5 to 0, +30* 5 to 0 5.7  0.5 vs 8.3  0.55 (max)
Schernthaner et al. [37] Insulin lispro MDI 0, +30 0 7.71  1.83 vs 8.66  2.13 (mean)
*Up to 15, 20 and 30 min after commencement of eating.
CSII, continuous subcutaneous insulin infusion; max, maximum postprandial glucose level; mean, mean postprandial glucose level; MDI,
multiple daily injections; n/a, not available.
FIGURE 4 Mean blood glucose levels after meal initiation in three
treatment arms: Pre: delivering an insulin glulisine bolus by insulin
pump 20 min prior to a meal (20 min); Start: immediately before the
meal (0 min); and Post: 20 min after meal initiation (+20 min).
Figure reproduced from Cobry et al. Diabetes Technol Ther 2010; 12:
173–137 [33].
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vs 1.27  1.89 [90 min]; 1.79  1.66 vs 0.99 
1.89 mmol/l [120 min], respectively). AUCs of all six treat-
ments showed insulin lispro 20 min (2.19 mmol/h/1) and
insulin 0 min (2.15 mmol/h/1) to be significantly
(P < 0.001) lower than all other treatments. The AUC of
insulin lispro +15 min was +1.98 mmol/h/1. In total, 13
hypoglycaemic events were experienced: for early hypogly-
caemia, there were three in the RHI 40 min group, one in
the RHI 20 min group, two in the insulin lispro 20 min
group and one in the insulin lispro +15 min group. There
was one late hypoglycaemic episode in each of the RHI
40 min, 20 min and 0 min groups and three in the insulin
lispro +15 min group. No hypoglycaemic events were seen
with insulin lispro 0 min. It should be noted that the pre-
meal glucose was not as well controlled as other studies, with
large variation (3.3–11.1 mmol/l) [36].
Schernthaner et al. [37] also performed a 6-month cross-
over study on 31 people with Type 1 diabetes receiving
insulin lispro either preprandially or postprandially for a 3-
month period followed by the alternate regimen for a further
3 months. This study was unique, as it examined clinical
outcomes by measuring HbA1c, fructosamine and eight-point
BG levels. HbA1c decreased in the preprandial group and
increased in the postprandial group (0.15  0.41% vs
+0.11  0.48%; P = 0.008). Fructosamine levels also
reduced in the preprandial group ( 15  31 lmol/l vs
1  39 lmol/l), although eight-point BG levels were not
statistically significantly different between the groups. This
study highlights the negative impact that postprandial insulin
administration can have on glycaemic control with long-term
use. There was no difference in hypoglycaemic events
between the two groups [37].
Jovanovic et al. [38] compared the injection of insulin
aspart immediately before mealtime to immediately after-
wards in 19 people with Type 1 diabetes on MDI regimens
and found that total glucose AUC during the meal test was
22% smaller when insulin aspart was injected immediately
before the study meal (mean [SE] 23 014 [1832] mg/dl/min)
than when injected immediately after the meal (mean [SE], 29
535 [2243] mg/dl/min; P < 0.001). There were some weak-
nesses in that study, however, because preprandial glucose
levels were higher on the postprandial injection study day
and the fat and protein content of the meals was not fixed,
with lower intake on days with pre-meal injections [38].
Bode et al. [39] conducted a double-blind, randomized,
crossover, active-controlled trial comparing 2-h postprandial
BG level response after 2 weeks of continuous s.c. insulin
infusion with faster aspart or insulin aspart. Insulin was
administered immediately before consumption of a stan-
dardized meal and all participants wore blinded CGM
devices. Faster aspart provided a statistically significantly
greater glucose-lowering effect after the meal than did insulin
aspart: DBG of 3.03 vs 4.02 mmol/l. At 1 h post-meal, BG
levels were 1.64 mmol/l lower with faster aspart than with
insulin aspart (P = 0.006). This study suggests potential
benefit with the newer, faster, rapid-acting analogue insulins
on postprandial hyperglycaemia when given pre-meal [39].
The impacts of using either insulin 15 min pre-meal, or a
comparison of aspart given 15 min pre-meal and the faster-
acting analogue just before eating, remain to be determined.
Data from the Type 1 exchange registry support our
findings, with the majority of people in the excellent control
group administering pre-meal boluses as recommended [40].
It is notable that most structured education programmes
and algorithms for dose adjustment are based on pre-meal
glucose (Dose Adjustment for Normal Eating [DAFNE],
Diabetes Teaching and Treatment Programme [DTTP]). As
CGM technologies become more widely used, patients will
be exposed to more post-meal glucose data. Indeed, in a
study using intermittently monitored continuous s.c. moni-
toring, in which the glucose sensor records a continuous trace
of plasma glucose-equivalent measures in the hours prior to
screening, there was a significant shift towards delivering
meal boluses 15–20 min pre-meal from immediate or post-
meal administration, as users identified timing of bolus as a
key factor in post-meal glucose control [41]. The American
Diabetes Association recommends checking post-meal glu-
cose at 2 h, aiming for a target of <10 mmol/l [11]. At 2 h,
glucose is likely to be falling, and there is a need for
recommendations that take into account the insulin on
board, which again may be influenced by the timing of the
bolus.
Dose timing may be less critical in people with Type 2
diabetes, at least while they retain useful amounts of
endogenous insulin. A study by Gredal et al. [42] assessed
the optimal dose and timing of aspart in people with Type 2
diabetes. No difference in postprandial glucose profile was
demonstrated whether insulin aspart 0.04 IU/kg was admin-
istrated 15 or 30 min before mealtime. Doubling the dose
increased the risk of hypoglycaemia [42].
Ratner et al. [43] investigated the effect of insulin
glulisine injected either preprandially (0–15 min) or post-
prandially (+20 min) on glycaemic control and weight gain
in people with Type 2 diabetes. Participants were also
taking insulin glargine once daily  metformin. This study
lasted for 52 weeks, with 322 people completing the study.
At study end, insulin glulisine achieved similar glycaemic
control whether it was administered before or after meals
(HbA1c: 7.04% pre-meal vs 7.16% post-meal; P = non-
significant). Overall hypoglycaemia incidence and severe
hypoglycaemia rates were not significantly different
between pre-meal and post-meal groups; however, symp-
tomatic and nocturnal hypoglycaemia rates were higher in
the postprandial group. There was no significant difference
in weight gain [43].
Many people with Type 2 diabetes requiring insulin
therapy use biphasic or mixed insulin. Warren et al. [44]
compared biphasic aspart insulin (BIAsp 30, a biphasic
formulation of insulin aspart, 30% soluble and 70%
protamine-crystallized) injected 5 min before or 15–20 min
ª 2017 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK. 7
Research article DIABETICMedicine
after eating in an elderly population (aged >65 years) with
Type 2 diabetes. Mean plasma glucose values during a 4-h
meal test at the end of each treatment were similar for pre-
and postprandial BIAsp 30 (8.5  3.2 mmol/l and
8.9  3.3 mmol/l, respectively; difference not significant).
The mean BG increment from self-measured BG values,
however, was slightly but significantly greater after post-
prandial injection than after preprandial injection (treatment
difference: 0.9 mmol/l, 95% CI 0.03;1.63). No increased
risk of hypoglycaemia was seen with postprandial injection
[44].
Effect of other factors on postprandial
glucose control
When interpreting data from the described studies, it is
important to consider other factors that can adversely
affect postprandial glycaemia and potentially skew results.
The nutritional content of food, particularly the protein
and fat content, has been shown to affect postprandial
glycaemia. Some studies have shown that meals containing
carbohydrates that are high in dietary fat cause sustained late
postprandial hyperglycaemia. One study showed that the
addition of 35 g dietary fat increased postprandial glucose
concentrations by 2.3 mmol/l at 5 h and another demon-
strated that the addition of 50 g fat caused significant
hyperglycaemia over 5 h [45,46]. Protein has also been
shown to increase postprandial glucose levels, with one study
reporting that the addition of 35 g of protein to a 30-g
carbohydrate meal resulted in a 2.6-mmol/l increase in BG at
5 h [47]. There are also data to suggest that food order has a
significant role to play. A study by Shukla et al. [48] showed
that when protein and fat were consumed 15 min before
carbohydrate, the mean post-meal glucose levels were lower
by 28.6% (P = 0.001), 36.7% (P = 0.001) and 16.8%
(P = 0.03) at 30, 60 and 120 min, respectively, and the
incremental AUC was 73% lower. The glycaemic index of
food may also affect postprandial BG levels, as foods with a
high glycaemic index cause a large and rapid rise in BG,
whereas those with a low glycaemic index produce small
fluctuations in BG [49]. It has also been shown that large
carbohydrate meals may contribute to late postprandial
hyperglycaemia [50]. These studies highlight the importance
of knowing and understanding the nutritional content of
meals, as this can have a bearing on prandial glucose levels
and insulin requirements. We may speculate that bolusing
15–20 min before eating is of most importance with high-
glycaemic index foods, and that dividing administration of
doses may allow optimum postprandial glucose control for
meals of high fat and/or protein content. One study found
that an 8-h dual-wave bolus given pre-meal using an insulin
pump provided the best postprandial glucose control after a
high-fat meal [51].
Gastric emptying rate is also an important variable that
can influence postprandial glycaemia in both people with and
without diabetes, with significant inter-individual variability.
Pre-meal glucose affects gastric emptying, with hypergly-
caemia causing a ‘physiological’ slowing, as may meal
composition and other concomitant medication such as
glucagon-like peptide-1 receptor agonists [52–54]. People
with gastroparesis may also need a different bolus profile,
such as a dual-wave or a square-wave, to mimic the delayed
gastric absorption of carbohydrate [55]. One study examined
the intra-individual variability in postprandial glucose excur-
sions in a small cohort of people with Type 1 diabetes on
MDI, using standardized test meals with either insulin lispro
(15 min pre-meal) or regular human insulin (30 min pre-
meal). The intra-individual coefficients of variance of the
mean glucose excursions after the meals were significant, and
also lower with insulin lispro, at most time points: 1 h, 66%
vs 71%; 2 h, 49% vs 69%; 4 h, 66% vs 75% and 5 h, 49%
vs 72% [56].
There are, of course, some circumstances in which safety
or practicality governs the timing of insulin. Examples may
be people working in critical environments or where they
cannot guarantee eating of food 15–20 min after a bolus,
when eating out at social events or when predicting the exact
carbohydrate content of the meal ahead is not possible. In
these situations, pre- rather than post-meal administration
remains optimal but, if safety or convenience leads to
occasional post-meal administration of prandial insulin,
rapid-acting analogues are the safer option.
Administration of fast-acting analogues by a parent
uncertain of a child’s appetite within 15 min after the child
starts to eat may be an acceptable compromise between
parental anxiety and normoglycaemia, but it should not be
allowed to become a habit as the child’s behaviour becomes
more predictable, and adults with diabetes should be
discouraged from postprandial injections.
Another special circumstance, in the opposite direction,
is pregnancy. A study by Murphy et al. [57] showed that
postprandial BG levels are impaired by significantly slower
glucose disposal in late gestation, with the authors
suggesting that optimal bolus timing in late pregnancy
may be 30–40 min pre-meal compared to 15–20 min in
early pregnancy.
The site at which s.c. insulin is injected can also affect the
PK characteristics of insulin. Abdominal injecting of rapid-
acting insulin analogues results in the highest concentration
of insulin at the earliest time when compared with insulin
administration in the arm, thigh or buttocks [58].
Conclusions
The data from the present review of the literature provide
clear clinical evidence for the superiority and safety of
injecting 15–20 min pre-food, with almost 30% lower post-
meal glucose levels, a lower AUC for hyperglycaemia and less
post-meal hypoglycaemia when the pre-meal glucose levels
are in range. We therefore recommend that people with
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diabetes should aim to do this whenever possible, accepting
that there may be individual circumstances when this is not
practical. Postprandial administration of rapid-acting insulin
analogues is a less effective method of controlling BG levels
in the postprandial phase, and carries a significant risk of
hypoglycaemia.
The PK/PD studies of rapid-acting insulin analogues show
that the time to maximum insulin levels is between 40 and
60 min, but time to peak insulin effect is up to 120 min after
injection. Given that BG levels peak before the maximum
peak effect of insulin has been reached, it makes sense to
administer rapid-acting insulin analogues 15–20 min before
mealtimes to try to synchronize BG and insulin peaks in an
attempt to avoid postprandial hyperglycaemia. Fear of
hypoglycaemia by adopting this approach may prevent
patients from following this advice but may be allayed by
discussion of the lack of insulin action during that time.
Indeed, the data show that risk of post-meal hypoglycaemia
is highest with analogue insulins when administered 20 min
after the start of eating. The delay in injecting after a meal in
adults with Type 1 diabetes using post-meal insulin admin-
istration may often be greater than that, which would be
expected to exacerbate the problems further.
As our understanding of post-meal glucose control
increases, we may need to develop better strategies to cope
with complex meals that may require different time–action
profiles. With the advent of newer faster-acting analogues,
we will need further clinical studies to understand the
optimum timing of these insulins; however, given the profile
of post-meal glucose excursions, the time to peak insulin
action would need to be <45 min if these insulins were to be
effectively used after eating.
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